Ovarian cancer market to more than quadruple by 2025, report

The ovarian cancer space across the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from around $1.2 billion in 2015 to over $5.2 billion by 2025, representing a strong compound annual growth rate of 15.5%.

According to research and consulting firm GlobalData’s latest report, the key driver of this growth will be the establishment of new standard of care (SOC) maintenance therapies in the first and second lines of treatment for newly-diagnosed and recurrent patients. The anticipated extended durations of therapy in the maintenance settings should fuel the sales of poly ADP-ribose polymerase (PARP) inhibitors and immune checkpoint modulators, as their efficacy data is expected to justify their expensive price tags.

Marc Hansel, healthcare analyst for GlobalData, explains: “PARP inhibitors are expected to be a major addition to the treatment paradigm for patients with deleterious germline or somatic BRCA mutations or BRCA-like phenotypes. AstraZeneca’s [LSE: AZN] PARP inhibitor, Lynparza (olaparib), enjoyed two years alone on the ovarian cancer market without direct competition until Clovis Oncology’s [Nasdaq: CLVS] Rubraca (rucaparib) joined the US market in December 2016.”